BRIDGE HCV
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Clinical Practice Guideline
HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C.
American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA), Last updated September 2021.
Simplified HCV Treatment Algorithm for Treatment-Naive Adults Without Cirrhosis
American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA). August 2020.
Simplified HCV Treatment Algorithm for Treatment-Naive Adults With Compensated Cirrhosis
American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA). August 2020.
Clinical Resources
A Guide to Comprehensive Hepatitis C Counseling and Testing.
Centers for Disease Control and Prevention (CDC).
Hepatitis C Online Tools and Calculators: APRI.
Hepatitis C Online: University of Washington
Hepatitis C Online Tools and Calculators: FIB-4.
Hepatitis C Online: University of Washington
HEP Drug Interactions.
University of Liverpool.
National Harm Reduction Coalition.
PREP-C: Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment.
Mount Sinai School of Medicine.
Rural Health Information Hub.
Action and Advocacy
Center for Health Law and Policy Innovation (CHLPI)
CHLPI advocates for legal, regulatory, and policy reforms to improve the health of underserved populations. It has played a pivotal role in removing Medicaid restrictions on HCV treatment.
Hepatitis Education Project (HEP)
HEP provides support, education, advocacy, and direct services for people affected by hepatitis, and works to raise hepatitis awareness among patients, medical providers, and the general public.
National Hepatitis Corrections Network (NHCN)
NHCN, managed by HEP, supports a public health approach to hepatitis education, prevention, testing, and treatment in prisons and jails.
National Viral Hepatitis Roundtable
National Viral Hepatitis Roundtable (NVHR) is a coalition working together to eliminate hepatitis B and C in the U.S. It offers practical online resources for practice management.
Substance Abuse and Mental Health Services Administration (SAMHSA): Locator Map
SAMHSA provides an interactive national map that facilitates identification of local resources and services for substance use and mental health disorders.
Patient Resources
The BodyPro — Project Inform
Project Inform promotes the development of effective HIV and HCV therapies; supports patients’ informed choices about their health; advocates for quality, affordable health care; and addresses medical strategies that prevent new infections.
Hepatitis C Information Center
The American Liver Foundation’s Hepatitis C Information Center website is a dedicated online information and resource center created in support of individuals impacted by HCV infection.
HepatitisC.net
HepatitisC.net is a website for people living with HCV that offers education, tools, and resources. Articles are written by people living with or cured of HCV, patient advocates, and medical providers.
Hepatitis C Questions and Answers for the Public
Centers for Disease Control and Prevention (CDC). Last reviewed April 2020.The CDC is a division within the US Department of Health and Human Services (DHHS), the principal agency for protecting the health of all Americans. This patient-directed website addresses basics across the HCV clinical continuum.
Suggested Readings
Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy.
Kushner T, Reau N. J Hepatol. 2021;74(3):734-741.
Hepatitis C testing among perinatally exposed infants.
Lopata SM, et al. Pediatrics. 2020;145(3):e20192482.
“Everybody living with a chronic disease is entitled to be cured”: challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
Goodyear T, et al. Int J Drug Policy. 2020;81:102766.
Treatment of HCV in persons who inject drugs: treatment as prevention.
Grebely J, Dore GJ. Clin Liver Dis. 2017;9(4):77-80.
Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists—the practitioner experience.
Marshall AD, et al. Drug Alcohol Depend. 2020;206:107705.
Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis.
Hajarizadeh B, et al. J Hepatol. 2020;72(4):643-657.
Concurrent initiation of hepatitis C and opioid use disorder treatment in people who inject drugs.
Rosenthal ES, et al. Clin Infect Dis. 2020;71(7):1715-1722.
Clients’ perceptions of barriers and facilitators to implementing hepatitis C virus care in homeless shelters.
Masson CL, et al. BMC Infect Dis. 2020;20(1):386.
Interactive PresentationHave You Ever Injected Drugs? What You Need to Know About Hepatitis C
Current or past injection drug use puts you at high risk for hepatitis C infection. But there is good news for those who are infected: New treatments are available that cure most people—even injection drug users. This video provides important information on your risk for Hepatitis C, getting tested, and—if you're infected—getting cured.
Opportunities for Current and New HCV Treaters
Relevant Resources
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
Informing the Future of NASH Diagnosis and Assessment
A PEP/PrEP Training Guide for Pharmacists
An Interactive Learning Experience
A Focus on Clinical Evidence and Guideline Recommendations
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
A Multidisciplinary Look at Early Diagnosis and Management
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
An Updated Clinician’s Guide to Assessment and Management
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
A Multidisciplinary Approach
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
A Phone-a-Friend CME Series – Volume 2
Incorporating New Data and Updated Guidelines Into Daily Practice
